Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cullinan Management Inc
(NQ:
CGEM
)
17.04
-0.69 (-3.89%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
394,192
Open
17.79
Bid (Size)
17.03 (30)
Ask (Size)
17.04 (1)
Prev. Close
17.73
Today's Range
17.02 - 17.79
52wk Range
7.640 - 19.68
Shares Outstanding
199,873,683
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023
March 14, 2024
CGEM stock results show that Cullinan Oncology beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Cullinan Oncology: Q4 Earnings Insights
March 14, 2024
Via
Benzinga
Performance
YTD
+60.91%
+60.91%
1 Month
-4.54%
-4.54%
3 Month
+69.55%
+69.55%
6 Month
+68.05%
+68.05%
1 Year
+62.60%
+62.60%
More News
Read More
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
March 01, 2024
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
February 27, 2024
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Recap: Cullinan Oncology Q3 Earnings
November 08, 2023
Via
Benzinga
Analyst Ratings for Cullinan Oncology
August 09, 2023
Via
Benzinga
Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
January 30, 2024
Via
Benzinga
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 18, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
December 14, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Analyst Ratings for Cullinan Oncology
July 07, 2023
Via
Benzinga
Analyst Expectations for Cullinan Oncology's Future
June 15, 2023
Via
Benzinga
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 08, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
November 03, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
October 30, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
September 06, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Expert Ratings for Cullinan Oncology
June 15, 2023
Via
Benzinga
4 Analysts Have This to Say About Cullinan Oncology
May 26, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
October 06, 2023
Via
Benzinga
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 10, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
August 09, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
July 31, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
June 15, 2023
Via
Benzinga
Why Shares of Cullinan Oncology Jumped This Week
June 09, 2023
Via
The Motley Fool
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
May 25, 2023
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.